SCHEMBL1316142

SCHEMBL1316142

CC(C)(C)OC(=O)c1ccc(-c2ccco2)cc1NC(=O)c1cc(N2CCOCC2)ccc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
WDR5 P61964 1/20 0.44
MAPT P10636 8/20 0.43
POLB P06746 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
KDM4E B2RXH2 2/20 0.43
NR4A1 P22736 1/20 0.43
HTT P42858 1/20 0.43
UBE2I P63279 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
ESR2 Q92731 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC2 Q92769 1/20 0.42
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12118065 0.92 SMN1; SMN2 (0.46) SMN1; SMN2WDR5MAPTPOLBNPSR1
SCHEMBL1316547 0.88 HDAC1 (0.45) SMN1; SMN2MAPTKMT2AMEN1ALDH1A1
SCHEMBL1319192 0.87 SMN1; SMN2 (0.48) SMN1; SMN2WDR5MAPTPOLBNPSR1
SCHEMBL1315941 0.85 LRRK2 (0.53) SMN1; SMN2WDR5MAPTPOLBNPSR1
SCHEMBL1317481 0.84 HDAC2 (0.45) WDR5POLBKDM4ECACNA1BAPBA1
SCHEMBL12118063 0.82 PRKDC (0.49) SMN1; SMN2MAPTKMT2AMEN1ALDH1A1
SCHEMBL1315406 0.80 HDAC2 (0.42) WDR5MAPTPOLBNPSR1KDM4E
SCHEMBL12118011 0.79 SCN9A (0.45) SMN1; SMN2MAPTKDM4EKMT2AMEN1
SCHEMBL1316253 0.79 HDAC1 (0.44) SMN1; SMN2WDR5MAPTNPSR1KDM4E
SCHEMBL12117757 0.79 HDAC2 (0.45) WDR5HDAC3HDAC2MCL1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-8492582-B2 N-acyl anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2013-07-23 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2011-11-10 US disclosed
EP-2385036-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2011-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275797-A1 N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF COL14A1, COL2A1, COL1A1 SMN1; SMN2 1917/4885WDR5 1442/4885MAPT 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.